pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » Histogenics Corporation (HSGX) market: only upside from these levels

Histogenics Corporation (HSGX) market: only upside from these levels

Posted on September 5, 2018 by PennyStockHaven in Commentary, Market Movers & Losers, Stock Picks

Histogenics Corp (NASDAQ: HSGX) shares were down 73% of their market value at time of publishing following the release data of its Phase 3 clinical trial of NeoCart that did not meet the primary endpoint of a statistically significant improvement in pain and function in a dual threshold responder analysis one year after treatment as compared to microfracture.

Histogenics CEO Adam Gridley said that regardless of study results the company still plans to seek FDA approval based on the data released Wednesday.

Approximately 71 percent of the patients receiving NeoCart exhibited clinically meaningful improvements in pain and function a year after having the cell-regenerating product implanted, compared to 62 percent of people who had undergone microfracture, a common knee surgery, according to the company. But that was not enough to meet the endpoint, or trial goal, that Histogenics initially established in 2009.

At the same time, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Histogenics (NASDAQ: HSGX), with a price target of $2. Ramakanth commented:

We maintain our Buy rating of HSGX and lower our 12-month price target to $2.00 per share, down from $3.50. We derive our price target based on a risk-adjusted net present value analysis of projected NeoCart revenues until 2027 assuming a 12% discount rate and a 3% terminal value. We derive an rNPV of $97M for NeoCart and add $9M in cash and cash equivalents to arrive at a 12-month price target of $1.99 per diluted share, which we round to $2.00. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) legal and intellectual property.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.8% and a 42.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

biotech penny stock, NASDAQ: HSGX

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018
  • Light Engine Design Corp (TLED): 50% gain into your pocket

    November 7, 2017
  • This Oil Company Is Poised For A Huge Run

    October 24, 2017
  • Curis, Inc. (CRIS) – Alert is still in Effect

    October 11, 2017
  • Curis, Inc. (CRIS) – Volume Alert (Technical Play)

    October 4, 2017
    Micro & Small Cap Stocks

    * required

    *



    *



     
    Remember, if you’re not fully satisfied with our service, you can always opt-out of receiving our newsletter. We don’t spam and we’ll never sell your email to anyone else. We respect our subscribers’ privacy.

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved